Dr. Habra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd, Unit 1461
Houston, TX 77030Phone+1 713-792-2841Fax+1 713-794-4065- Is this information wrong?
Summary
- I am an oncologic endocrinologist at MD Anderson Cancer Center.
My clinical practice focuses on endocrine tumors and endocrine complications in cancer patients with special interest in adrenal and thyroid tumors.
Education & Training
- Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
- University of Missouri-ColumbiaResidency, Internal Medicine, 1999 - 2002
- University of Aleppo Faculty of MedicineClass of 1995
Certifications & Licensure
- FL State Medical License 2021 - Present
- TN State Medical License 2024 - 2026
- GA State Medical License 2024 - 2025
- TX State Medical License 2008 - 2025
- OK State Medical License 2020 - 2025
- LA State Medical License 2024 - 2024
- AZ State Medical License 2024 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Clinical Trials
- Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Start of enrollment: 2018 Feb 26
- Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Start of enrollment: 2018 Aug 20
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Start of enrollment: 2023 Mar 23
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.Gina Tamsen, Damaris Cruz-Goldberg, James Long, Roland Bassett, Robert Dantzer, Vania Balderrama-Brondani, Camilo Jimenez, Mouhammed Amir Habra, Matthew T Campbell, Je...> ;The Lancet. Oncology. 2024 Apr 9
- Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.Vania Balderrama-Brondani, Gina Tamsen, James P Long, Joshua Ochieng, Cara Haymaker, Matthew T Campbell, Camilo Jimenez, Leonardo P Marcal, Jeena Varghese, Amishi Y Sh...> ;The Lancet. Oncology. 2024 Apr 9
- 2 citationsThe effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.Alaa Sada, Trenton R Foster, Ruaa Al-Ward, Sahar Sawani, HElaine Charchar, Reza Pishdad, Anat Ben-Shlomo, Benzon M Dy, Melanie L Lyden, Emily Bergsland, Sina Jasim, Ni...> ;Surgery. 2024 Jan 1
- Join now to see all
Press Mentions
- Management of Adrenocortical CarcinomaApril 10th, 2019
- Lenvatinib Shows Promise for Patients with Radioiodine-Refractory Thyroid CancerFebruary 12th, 2015
- A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy After Primary Surgical Resection in Patients with Adrenocortical Carcinoma, "Beyond the Abstract," by Mouhammed Amir Habra, MDFebruary 28th, 2013
Professional Memberships
- Fellow
- Fellow
- Member
- Member
Other Languages
- Arabic
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: